← Back to All US Stocks

Natera, Inc. (NTRA) Stock Fundamental Analysis & AI Rating 2026

NTRA Nasdaq Services-Medical Laboratories DE CIK: 0001604821
Updated This Month • Analysis: May 9, 2026 • SEC Data: 2026-03-31
Combined AI Rating
BUY
64% Confidence
AGREEMENT
HOLD
55% Conf
BUY
74% Conf

📊 NTRA Key Takeaways

Revenue: $696.6M
Net Margin: -12.2%
Free Cash Flow: $18.0M
Current Ratio: 2.96x
Debt/Equity: 0.16x
EPS: $-0.60
AI Rating: HOLD with 55% confidence
Natera, Inc. (NTRA) receives a BUY rating with 64% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $696.6M, net profit margin of -12.2%, and return on equity (ROE) of -4.8%, Natera, Inc. demonstrates strong fundamentals in the Healthcare sector. Below is our complete NTRA stock analysis for 2026.

Is Natera, Inc. (NTRA) a Good Investment?

Claude

Natera demonstrates robust 36% revenue growth with positive free cash flow ($18M) and a fortress balance sheet ($1.1B cash, 0.16x D/E), but operates at significant losses with -13.4% operating margin and -12.2% net margin, indicating structural profitability challenges at scale. The company has sufficient liquidity to sustain operations, but path to profitability remains unclear and requires material operational improvement.

ChatGPT

Natera shows strong fundamentals with 36% revenue growth, ample liquidity, low leverage, and positive operating and free cash flow despite GAAP losses. If operating leverage continues and margins improve, the balance sheet provides sufficient runway to reach sustainable profitability.

Why Buy Natera, Inc. Stock? NTRA Key Strengths

Claude
  • + Strong revenue growth of 35.9% YoY demonstrates market demand and customer acquisition momentum
  • + Positive free cash flow of $18M and operating cash flow of $40.2M despite net losses indicates operational cash generation capability
  • + Fortress balance sheet with $1.1B cash reserves, very low leverage (0.16x D/E), and strong liquidity ratios (2.96x current, 2.83x quick)
ChatGPT
  • + Rapid topline growth (+35.9% YoY)
  • + Robust liquidity and low leverage (3.39x current ratio, 0.17x D/E)
  • + Positive operating cash flow and FCF

NTRA Stock Risks: Natera, Inc. Investment Risks

Claude
  • ! Severe profitability deficit: -$93.5M operating loss on $696.6M revenue with negative operating and net margins despite scale
  • ! Razor-thin free cash flow margins at 2.6% with minimal profitability headroom relative to revenue base
  • ! Gross profit anomaly ($723.5M exceeds revenue of $696.6M) suggests accounting complexity or data quality issues requiring clarification
  • ! High insider activity (43 Form 4 filings in 90 days) warrants investigation for potential insider confidence concerns
ChatGPT
  • ! Persistent operating losses and negative interest coverage
  • ! Gross margin pressure from reimbursement/pricing dynamics
  • ! Higher capex needs could compress FCF if growth slows

Key Metrics to Watch

Claude
  • * Operating margin trajectory - critical inflection point if company can achieve breakeven or positive operating leverage from revenue growth
  • * Free cash flow sustainability and margin expansion - verify whether FCF improvements are achievable as company scales
  • * Gross profit reconciliation - resolve accounting treatment and verify no red flags in cost structure or revenue recognition
ChatGPT
  • * Operating margin trajectory
  • * Free cash flow margin

Natera, Inc. (NTRA) Financial Metrics & Key Ratios

Revenue
$696.6M
Net Income
$-85.1M
EPS (Diluted)
$-0.60
Free Cash Flow
$18.0M
Total Assets
$2.6B
Cash Position
$1.1B

💡 AI Analyst Insight

The relatively thin 2.6% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.96x current ratio provides a solid financial cushion.

NTRA Profit Margin, ROE & Profitability Analysis

Gross Margin 103.9%
Operating Margin -13.4%
Net Margin -12.2%
ROE -4.8%
ROA -3.3%
FCF Margin 2.6%

NTRA vs Healthcare Sector: How Natera, Inc. Compares

How Natera, Inc. compares to Healthcare sector averages

Net Margin
NTRA -12.2%
vs
Sector Avg 12.0%
NTRA Sector
ROE
NTRA -4.8%
vs
Sector Avg 15.0%
NTRA Sector
Current Ratio
NTRA 3.0x
vs
Sector Avg 2.0x
NTRA Sector
Debt/Equity
NTRA 0.2x
vs
Sector Avg 0.6x
NTRA Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Natera, Inc. Stock Overvalued? NTRA Valuation Analysis 2026

Based on fundamental analysis, Natera, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-4.8%
Sector avg: 15%
Net Profit Margin
-12.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.16x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Natera, Inc. Balance Sheet: NTRA Debt, Cash & Liquidity

Current Ratio
2.96x
Quick Ratio
2.83x
Debt/Equity
0.16x
Debt/Assets
32.1%
Interest Coverage
-22.98x
Long-term Debt
$282.9M

NTRA Revenue & Earnings Growth: 5-Year Financial Trend

NTRA 5-year financial data: Year 2021: Revenue $625.5M, Net Income -$124.8M, EPS $-1.79. Year 2022: Revenue $820.2M, Net Income -$229.7M, EPS $-2.84. Year 2023: Revenue $1.1B, Net Income -$471.7M, EPS $-5.21. Year 2024: Revenue $1.7B, Net Income -$547.8M, EPS $-5.57. Year 2025: Revenue $2.3B, Net Income -$434.8M, EPS $-3.78.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Natera, Inc.'s revenue has grown significantly by 269% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.78 indicates the company is currently unprofitable.

NTRA Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
2.6%
Free cash flow / Revenue

NTRA Quarterly Earnings & Performance

Quarterly financial performance data for Natera, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $501.8M -$66.9M $-0.50
Q3 2025 $439.8M -$31.6M $-0.26
Q2 2025 $413.4M -$37.5M $-0.30
Q1 2025 $367.7M -$66.9M $-0.50
Q3 2024 $268.3M -$31.6M $-0.26
Q2 2024 $261.4M -$37.5M $-0.30
Q1 2024 $241.8M -$67.6M $-0.56
Q3 2023 $210.6M -$109.0M $-0.95

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Natera, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$40.2M
Cash generated from operations
Capital Expenditures
$22.1M
Investment in assets
Dividends
None
No dividend program

NTRA SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Natera, Inc. (CIK: 0001604821)

📋 Recent SEC Filings

Date Form Document Action
May 15, 2026 4 xslF345X06/form4-05152026_090501.xml View →
May 8, 2026 10-Q ntra-20260331.htm View →
May 7, 2026 8-K ntra-20260507.htm View →
May 6, 2026 4 xslF345X06/form4-05062026_090501.xml View →
May 5, 2026 4 xslF345X06/form4-05052026_090501.xml View →

Frequently Asked Questions about NTRA

What is the AI rating for NTRA?

Natera, Inc. (NTRA) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are NTRA's key strengths?

Claude: Strong revenue growth of 35.9% YoY demonstrates market demand and customer acquisition momentum. Positive free cash flow of $18M and operating cash flow of $40.2M despite net losses indicates operational cash generation capability. ChatGPT: Rapid topline growth (+35.9% YoY). Robust liquidity and low leverage (3.39x current ratio, 0.17x D/E).

What are the risks of investing in NTRA?

Claude: Severe profitability deficit: -$93.5M operating loss on $696.6M revenue with negative operating and net margins despite scale. Razor-thin free cash flow margins at 2.6% with minimal profitability headroom relative to revenue base. ChatGPT: Persistent operating losses and negative interest coverage. Gross margin pressure from reimbursement/pricing dynamics.

What is NTRA's revenue and growth?

Natera, Inc. reported revenue of $696.6M.

Does NTRA pay dividends?

Natera, Inc. does not currently pay dividends.

Where can I find NTRA SEC filings?

Official SEC filings for Natera, Inc. (CIK: 0001604821) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NTRA's EPS?

Natera, Inc. has a diluted EPS of $-0.60.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is NTRA a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Natera, Inc. has a BUY rating with 64% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is NTRA stock overvalued or undervalued?

Valuation metrics for NTRA: ROE of -4.8% (sector avg: 15%), net margin of -12.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy NTRA stock in 2026?

Our dual AI analysis gives Natera, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NTRA's free cash flow?

Natera, Inc.'s operating cash flow is $40.2M, with capital expenditures of $22.1M. FCF margin is 2.6%.

How does NTRA compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -12.2% (avg: 12%), ROE -4.8% (avg: 15%), current ratio 2.96 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% ANET 88% RDDT 88% KNSL 88% MGRE 88%
Sector: All Healthcare Stocks →
Browse: Buy Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 9, 2026 | Data as of: 2026-03-31 | Powered by Claude AI